Gulf Scientific Corporation’s Post

Their abstract: Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC.

Asciminib, a BCR::ABL1 inhibitor targeting the ABL myristoyl pocket, demonstrated superior efficacy and safety compared to tyrosine kinase inhibitors in the phase 3 ASC4FIRST trial for newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Read Viewpoint in Med by Cell Press. #ChronicMyeloidLeukemia #CML #TyrosineKinaseInhibitors #Asciminib #ASC4FIRST https://lnkd.in/ei6cKc48

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based #PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of #SJ45566, a potent and orally bioavailable LCK #PROTAC. #Protac #PDC #SmallMolecule #Medchem #Medcinal #FFS #FTE #CDMO #CMC

📢 Congrats! Our client's research team published in #CancerResearch (IF=11.2) entitled "Foretinib ls Effective in Acute Myeloid Leukemia byInhibitingFLT3andOvercomingSecondaryMutations That DriveResistanceto Quizartiniband Gilteritinib". The research utilized TargetMol's three products: T3113 Foretinib: https://lnkd.in/eghs3RSs T2066 Quizartinib: https://lnkd.in/eedufhhH C0001 Protease inhibitor: https://lnkd.in/eHqMiYg4 They are choices made by the experts. You deserve to have it! ▶ Get the full article here: https://lnkd.in/eeRpU_VA ▶ For more information, please refer to the following image: #cancerresearch #smallmolecules #inhibitor #compounds #TargetMol

New from Immune-Onc Therapeutics at #EHA2024! Today, we will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia (#CMML).  The study shows early and sustained complete remissions among CMML patients, regardless of their prognosis or mutation status. Learn more: https://lnkd.in/gZgdrvr6

Inhibikase is developing IkT-001Pro to provide people suffering from chronic myelogenous leukemia (CML) with a new and improved, safer alternative to imatinib. Learn about our development of IkT-001Pro for CML here: https://bit.ly/3fMhg8O

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

Today, we announced the first patient has been dosed in our KOMET-008 trial of our menin inhibitor ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC, for the treatment of relapsed or refractory acute myeloid leukemia.    Learn more about the KOMET-008 study and why we believe #ziftomenib has ideal properties as a combination agent for NPM1-mutant and KMT2A-rearranged #AML.   https://bit.ly/49t2TRA

Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia https://lnkd.in/e-hnxTjt

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells. https://ja.ma/3JmNG9l